These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
493 related articles for article (PubMed ID: 27014936)
1. Inhibition of Protease-Epithelial Sodium Channel Signaling Improves Mucociliary Function in Cystic Fibrosis Airways. Reihill JA; Walker B; Hamilton RA; Ferguson TE; Elborn JS; Stutts MJ; Harvey BJ; Saint-Criq V; Hendrick SM; Martin SL Am J Respir Crit Care Med; 2016 Sep; 194(6):701-10. PubMed ID: 27014936 [TBL] [Abstract][Full Text] [Related]
2. SPX-101 Is a Novel Epithelial Sodium Channel-targeted Therapeutic for Cystic Fibrosis That Restores Mucus Transport. Scott DW; Walker MP; Sesma J; Wu B; Stuhlmiller TJ; Sabater JR; Abraham WM; Crowder TM; Christensen DJ; Tarran R Am J Respir Crit Care Med; 2017 Sep; 196(6):734-744. PubMed ID: 28481660 [TBL] [Abstract][Full Text] [Related]
3. The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis lung disease. Moore PJ; Tarran R Expert Opin Ther Targets; 2018 Aug; 22(8):687-701. PubMed ID: 30028216 [TBL] [Abstract][Full Text] [Related]
4. Soluble mediators, not cilia, determine airway surface liquid volume in normal and cystic fibrosis superficial airway epithelia. Tarran R; Trout L; Donaldson SH; Boucher RC J Gen Physiol; 2006 May; 127(5):591-604. PubMed ID: 16636206 [TBL] [Abstract][Full Text] [Related]
5. Effect of neutrophil elastase and its inhibitor EPI-hNE4 on transepithelial sodium transport across normal and cystic fibrosis human nasal epithelial cells. Prulière-Escabasse V; Clerici C; Vuagniaux G; Coste A; Escudier E; Planès C Respir Res; 2010 Oct; 11(1):141. PubMed ID: 20932306 [TBL] [Abstract][Full Text] [Related]
7. A highly selective, cell-permeable furin inhibitor BOS-318 rescues key features of cystic fibrosis airway disease. Douglas LEJ; Reihill JA; Ho MWY; Axten JM; Campobasso N; Schneck JL; Rendina AR; Wilcoxen KM; Martin SL Cell Chem Biol; 2022 Jun; 29(6):947-957.e8. PubMed ID: 35202587 [TBL] [Abstract][Full Text] [Related]
8. Airway surface liquid volume regulates ENaC by altering the serine protease-protease inhibitor balance: a mechanism for sodium hyperabsorption in cystic fibrosis. Myerburg MM; Butterworth MB; McKenna EE; Peters KW; Frizzell RA; Kleyman TR; Pilewski JM J Biol Chem; 2006 Sep; 281(38):27942-9. PubMed ID: 16873367 [TBL] [Abstract][Full Text] [Related]
9. The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis. Shei RJ; Peabody JE; Kaza N; Rowe SM Curr Opin Pharmacol; 2018 Dec; 43():152-165. PubMed ID: 30340955 [TBL] [Abstract][Full Text] [Related]
10. ENaC inhibitors and airway re-hydration in cystic fibrosis: state of the art. Althaus M Curr Mol Pharmacol; 2013 Mar; 6(1):3-12. PubMed ID: 23547930 [TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of the epithelial sodium channel inhibitor AZD5634 and implications on human translation. Åstrand A; Libby EF; Shei RJ; Lever JEP; Kaza N; Adewale AT; Boitet E; Edwards L; Hemmerling M; Root J; Lindberg B; Wingren C; Malmgren A; Sabater J; Rowe SM Am J Physiol Lung Cell Mol Physiol; 2022 Nov; 323(5):L536-L547. PubMed ID: 36098422 [TBL] [Abstract][Full Text] [Related]
12. Prostasin expression is regulated by airway surface liquid volume and is increased in cystic fibrosis. Myerburg MM; McKenna EE; Luke CJ; Frizzell RA; Kleyman TR; Pilewski JM Am J Physiol Lung Cell Mol Physiol; 2008 May; 294(5):L932-41. PubMed ID: 18310226 [TBL] [Abstract][Full Text] [Related]
13. Pharmacotherapy of the ion transport defect in cystic fibrosis: role of purinergic receptor agonists and other potential therapeutics. Kunzelmann K; Mall M Am J Respir Med; 2003; 2(4):299-309. PubMed ID: 14719996 [TBL] [Abstract][Full Text] [Related]